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Background and purpose: The role of adjuvant radiotherapy for central neurocytomas (CNs) is not clear.
Therefore, we aimed to examine the clinical outcomes of treating histologically confirmed CNs with adjuvant RT
after surgical resection.
Material and methods: Sixty-three CN patients were retrospectively evaluated: 24 patients underwent gross total
resection (GTR); 28, subtotal resection (STR); 9, partial resection (PR), and 2, biopsy (Bx). They underwent adjuvant RT
after surgery (median dose, 54 Gy).
Results: The median follow-up was 69 months (15–129 months). The 5-year overall survival (OS) and 5-year
progression-free survival (PFS) were 94.4% and 95% after GTR + RT, 96.4% and 100% after STR + RT, and 100% and
90.9% after PR + RT. Only three patients had tumor recurrence: at the primary site at 30 and 24 months in two
GTR + PR patients, and dissemination to the spinal cord at 75 months in one STR + RT patient. Thirty-eight (63.3%)
patients experienced late neurotoxicity (28, grade 1; 7, grade 2; 3, grade 3). Short-term memory impairment was the
most common toxicity.
Conclusions: RT after incomplete resection (IR) led to OS and PFS comparable to those for GTR. Considering the
excellent outcomes and limited late toxicity, adjuvant RT maybe a good option for CN patients who undergo IR.
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Central neurocytomas (CNs) of World Health Organization
(WHO) grade II [1] are uncommon tumors of the central
nervous system and represent approximately 0.25–0.5% of
all intracranial tumors. CN was described for the first time
in 1982 by Hassoun and co-workers, and, by the early
1990s, it had become a well-defined clinical and patho-
logical entity [2]. CNs are typically located supratentorially
in the lateral ventricle(s) and/or the third ventricle. CN
used to be considered a benign tumor due to the excellent
clinical outcomes after treatment. However, long-term
follow-up showed that CNs had a higher recurrence rate
than expected, even after complete resection [3].
Because of the rarity of this tumor, no randomized
clinical trials on CNs have been performed. Treatment* Correspondence: neure55@126.com; ttyy6611@126.com
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unless otherwise stated.strategies have been based on case reports and retro-
spective studies on small populations [4-6]. Surgery is
the mainstay of treatment, and the extent of surgery is
the most important prognostic factor affecting clinical
outcomes [7]. In addition, radiotherapy (RT) can suc-
cessfully control residual tumor after incomplete resec-
tion or recurrence [3,8]. It is important to investigate the
role of adjuvant RT after resection, given the dismal local
control rates in CN patients who undergo incomplete
resection (IR). For example, in a study of 45 CN patients
[3], one-third of the patients developed recurrence after
gross tumor resection (GTR). The recurrence rates were
even worse in patients who underwent IR. Rades et al. [9]
conducted a meta-analysis of all the published data since
1982 from 91 centers and reported that the 10-year local
control rate was only 35% in the 109 CN patients who re-
ceived IR. The role of adjuvant RT after resection remains
controversial, and the standard treatment for this tumor
has not yet been established [7,9-14]. The main concern
about the use of adjuvant RT in CN patients is that it maytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Chen et al. Radiation Oncology 2014, 9:242 Page 2 of 8
http://www.ro-journal.com/content/9/1/242increase the risk of late neurotoxicity in these patients
[4,5]. However, neurotoxicity of RT in patients with CN
has not been reported till now, and the concerns about
radiotoxicity mainly come from the long-term toxicity ob-
served in cases of other low-grade primary cerebral neo-
plasms like glioma [15].
Here, we retrospectively investigated the long-term
survival and late toxicities associated with adjuvant RT
for neurocytoma; we hope that these findings will help




Sixty-three patients with CN underwent surgical resec-
tion between January 2001 and October 2010 at Beijing
Tiantan Hospital. All the patients received adjuvant RT
after surgical resection at Beijing Tiantan Hospital,
Beijing Shijitan Hospital or Beijing Puren Hospital. Insti-
tutional review board approval was obtained at these
hospitals for retrospective review of the data. In all the
patients, the CN diagnosis was confirmed by pathological
tests. The dates of patients’ follow-up appointments were
obtained through a review of hospital records, telephone
interviews, and patient consultations.
Treatment
Of the 63 patients with CN, 24 underwent gross total re-
section (GTR); 28, subtotal resection (STR); 9, partial re-
section (PR); and 2, biopsy only (Bx). The extent of
resection was assessed by contrast-enhanced MR within
2 weeks after surgery. Based on the surgeon’s intraopera-
tive observation and the MR image, the extent of resec-
tion was classified as GTR (absence of a macroscopically
visible residue), STR (less than 10% residue remaining)
or PR (10–50% residue remaining). Patient selection for
postoperative RT was mostly based on the surgeon’s
discretion. Because there is no standard management
procedure for this rare malignant tumor, a majority of
surgeons at Tiantan Hospital preferred adjuvant RT to
decrease the chances of recurrence. From the 63 pa-
tients, 38 (60.3%) were treated with conventional focal
RT, and 25 (39.7%) with three-dimensional conformal
RT (3D-CRT, n = 18) or intensity-modulated radiation
therapy (IMRT, n = 7). Simulation was performed gener-
ally a month after surgical resection. The median inter-
val between surgery and RT was 47 days (range, 13 to
160 days).
Tumor volume is best defined using pre- and postop-
erative imaging. The planning target volume (PTV) rep-
resented a 3-mm geometric expansion of the clinical
target volume, which was an anatomically constrained
10-mm expansion of the gross-residual tumor and/or
tumor bed. In the whole series, the median total dosewas 54 Gy (range, 46–60 Gy), and it was delivered in
1.8–2 Gy daily fractions. All patients completed RT ac-
cording to the schedule.
Follow-up
Follow-up ended on September 1, 2012. Fifty-two (82.5%,
52/63) patients underwent contrast-enhanced MRI of the
brain every year after radiation, while eleven (17.5%, 11/
63) patients discontinued the MRI scans after 1 to 4 years
of follow-up. The median follow-up was 69 months, and
the mean follow-up was 66 months (range, 15–129
months). Overall survival (OS) was calculated from the
time of surgery until death or last follow-up, and
progression-free survival (PFS) was calculated from the
time of surgery until tumor recurrence or last follow-up.
The date of progression was confirmed retrospectively
based on the findings from the MRI scans or based on
symptomatic deterioration consistent with tumor progres-
sion. Toxicity was scored retrospectively using the Na-
tional Cancer Institute Common Terminology Criteria for
Adverse Events version 4.0 [16].
Statistical analysis
The Kaplan-Meier method was used to estimate the
time from surgery to relapse and death, and the log-rank
test was used to compare survival between groups. All
analyses were carried out using the SPSS 17.0 statistical




The patient characteristics are shown in Table 1. The
majority of patients presented with symptoms of in-
creased intracranial pressure, including headache (43
cases, 67.2%) and nausea and vomiting (15 cases, 23.4%).
The other symptoms included visual disturbance (17.2%),
seizure (1.6%), dizziness (6.4%), sensory disturbance (4.8%),
and others (6.4%). The involved areas included the left lat-
eral ventricle (47.6%), right lateral ventricle (39.7%), and
both lateral ventricles (12.7%). The tumors extended into
the third ventricle in three cases. The median Karnofsky
score was 90 (range, 30–100) before radiation. There were
more patients with younger age (<28 years) in the GTR +
RT group (18/24, 75%) than other groups (p = 0.005).
Other factors including gender (p = 0.288) and tumor lo-
cation (p = 0.984) were evenly distributed between groups.
Survival
Among the 63 CN patients, 42 patients were alive with
no evidence of disease, and 8 were alive with stable dis-
ease. Eleven patients did not undergo MRI in recent
years but had no symptoms of recurrence. Only two pa-
tients have died to date: one of them had undergone










Nausea and vomiting 15 23.4
Visual disturbance 11 17.2
Others 12 18.8
Tumor location (n)
Left lateral ventricle 30 47.6
Right lateral ventricle 25 39.7
Both lateral ventricle 8 12.7
Initial therapy (n)
GTR + RT 24 38.1
STR + RT 28 45.9
PR + RT 9 14.3
Bx + RT 2 3.2
Abbreviations: GTR gross total resection, STR subtotal resection, PR partial
resection, Bx biopsy, RT radiotherapy.




























Figure 2 Progression-free survival in the three groups: no
statistically significant differences were observed between the
three groups.
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rence, while the other had undergone STR and adjuvant
RT and died of unrelated causes 15 months after surgery.
The 5-year OS was 96.6% and the 5-year PFS was 96.5%
in all the patients (Figure 1). The 5-year OS and 5-year
PFS were 94.4% and 95% respectively after GTR + RT,
96.4% and 100% respectively after STR + RT, and 100%
and 90.9% respectively after PR + RT. No statistically sig-
nificant differences were observed between the three
groups with regard to the 5-year OS (p = 0.787) or 5-year





















Figure 1 Overall survival and progression-free survival in all
the patients.tumor diameter (≤5 cm vs. >5 cm), Karnofsky Perform-
ance Scale (KPS) score before RT (KPS ≤70 vs. >70), total
radiation dose (≤54 Gy vs. >54 Gy), radiation technique
(conventional RT vs. 3D-CRT/IMRT) and tumor location
(unilateral ventricle vs. both ventricles) had no impact on
OS or PFS (P >0.05).
Two patients underwent stereotactic biopsy and RT
with total doses of 58 Gy and 54 Gy, which resulted in
tumor shrinkage. One underwent STR at 5 months after
RT and survived for 65 months without tumor progres-
sion; the other patient survived for 91 months after RT
and is still alive without tumor recurrence.
Recurrence and salvage treatment
Three patients had recurrences during follow-up. Among
them, two patients had recurrences at the primary site at
30 months and 24 months after GTR and adjuvant RT,
and underwent salvage re-resection; one of them died of
tumor progression 3 months after surgery and the other is
still alive, at 129 months after surgery. The third patient
underwent STR and adjuvant RT with a total dose of
56 Gy and had tumor dissemination to the spinal cord at
76 months after surgery. Salvage RT was performed on
the recurrent lesion, and this patient is still alive with re-
sidual disease (Table 2). One of three patients combined
with the third ventricle invasion had recurrence.
Toxicity
The data on toxicity were available for 60 patients. Among
them, 38 (63.3%) patients experienced late neurotoxicity
(grade 1, n = 28; grade 2, n = 7; grade 3, n = 3). Short-term
memory impairment was the most common toxicity. At
the time of follow-up, 28 patients (28/60, 46.7%) had grade
1 short-term memory impairment, two of whom also had
grade 1 motor deficit. Grade 2 neurotoxicity (7/60, 11.7%)
included cognitive disturbance (n = 3), motor deficit (n =
3), seizure (n = 1), involuntary movements (n = 1) and
hemianopsia (n = 1); although these conditions affected
the activities of daily living of the affected patients, they
Table 2 Characteristics of the three patients with tumor progression after surgery
Patient no. Therapy TTP (mo) Recurrence site Salvage treatment TAP (mo) Last known status
1 GTR + RT (54 Gy) 30 Primary site PR 3 Dead, with disease
2 PR + RT (54 Gy) 24 Primary site GTR 129 Alive, no disease
3 STR + RT (54 Gy) 76 Dissemination (spinal cord) RT 9 Alive, with disease
Abbreviations: GTR gross total resection, PR partial resection, STR subtotal resection, TTP time to progression, TAP time after progression.
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patients (3/60, 5%) had grade 3 late neurotoxicity, includ-
ing decreased vision (n = 1) and severe cognitive disability
(n = 2). The first patient developed severe visual disturb-
ance after partial resection and now requires assistance
with his daily activities. The second patient had hydro-
cephalus and intracranial infection 4 weeks after surgery,
and consequently developed irreversible grade 3 cognitive
disturbance. The third patient developed cerebral infarc-
tion 5 years after RT, and had unilateral limb weakness
and severe cognitive deficit at the time of follow-up.
Dosimetric comparison was performed in 25 patients
who were treated with modern radiation techniques (18
with 3D-CRT and 7 with IMRT); the mean and maximum
doses for organs at risk (OARs) were not significantly dif-
ferent between the group that exhibited neurotoxicity and
the group that did not (Table 3). The hippocampus had
not been delineated as an OAR in the previous treatment
plans, so we re-planned the dosimetric comparison in
order to add the hippocampus as an OAR. No significant
difference was observed between the group that showed
memory impairment and the group that did not, with re-
gard to the mean and maximum radiation doses delivered
to the hippocampus (p >0.05).Table 3 Mean and max doses for PTVs and OARs in the
group with neurotoxicities versus the group with no
neurotoxicities
Neurotoxicity No neurotoxicity p
Dose (cGy) SD Dose (cGy) SD
PTV Max 5736 365 5670 394 0.641
mean 5470 348 5420 390 0.553
Brainstem max 4809 1618 4340 1393 0.837
mean 1389 800 874 689 0.462
Optic nerve max 198 188 155 120 0.755
mean 126 89 98 77 0.539
Left len max 131 204 96 189 0.764
mean 52 28 34 30 0.781
Right len max 51 18 34 22 0.540
mean 45 15 29 19 0.458
Hippocampus max 3665 1753 4185 1804 0.740
(both sides) mean 1947 1058 1592 772 0.303
Abbreviations: PTV planning target volume, OAR organ at risk.Discussion
To the best of our knowledge, this is one of the largest
original studies investigating the long-term survival,
local control and toxicity outcomes of adjuvant RT for
CN. To date, data on the long-term outcomes of RT
have been limited (Table 4). One meta-analysis [9] did
show that RT improved the 10-year OS and 10-year LC
in patients who underwent IR; moreover, this study also
showed that RT significantly improved the OS and LC in
cases of both typical CN and atypical CN. However, the
results of the published meta-analysis were limited by
the fact that it was conducted on preexisting published
data from many institutions. Our results suggested that
the addition of adjuvant RT led to the comparable sur-
vival outcomes to those who underwent GTR.
In this study, only three patients had recurrences dur-
ing follow-up. According to the published data, the ex-
tent of resection is the most important prognostic factor,
local control is better after GTR than after IR [14]. In
some studies, high MIB-1proliferation index is also a
prognostic factor which is associated with poorer local
control [18-20]. Radiation is important factor that can
retard residual tumor growth and improve local control
[14], but the effect of radiation dose to local control
remained unclear and should be addressed. The local
control rate in our study is excellent, even in patients
who underwent IR and adjuvant RT. Tumor location
seemed to be irrelevant to local recurrence, but involve-
ment of periventricular parenchyma was associated with
poor local control in some cases [21]. In our study, one
of three patients with the lateral ventricle and the third
ventricle involvement had recurrence. It is hard to draw
conclusion from such limited dada, but we guess that
the extent of tumor invasion may affect the local recur-
rence and deserve further investigation. Other factors
such as age and gender may not correlate to local recur-
rence based on the published data.
Neurotoxicity of RT in patients with CN has not been
reported till now. Although Hallock et al. [13] did report
the first large study on toxicity outcomes in CN patients,
mainly the sequelae of surgery, only one patient received
adjuvant RT (1/19) in their study. Our results showed
that surgery plus adjuvant RT produced minimal late
toxicity: only seven (11.7%) and three patients (5%) had
grade 2 and 3 late toxicity, respectively, and no grade 4
Table 4 Findings of some large retrospective studies on central neurocytomas
Author Year N Treatment OS LC F/U
(median)
Progression
5-year (%) 10-year (%) 5-year (%) 10-year (%)
Current study 2013 63 GTR + RT(24) 96.6 N/A 96.5 N/A 69 mo GTR + RT(1/24)
STR + RT(28) (15–129) STR + RT(1/28)
PR + RT(9) PR + RT(1/9)
Bx + RT(2) Bx + RT(0/2)





Hallock et al. [13] 2011 19 GTR(10) N/A 82 N/A 60 104.5 mo GTR(1/10)
STR(8) (0.75–261.7) STR(4/8)
STR + RT(1) STR + RT(1/1)





Lenzi et al. [17] 2006 20 GTR(10) N/A N/A N/A N/A 7 y (3–20) GTR(1/10)
STR + RT(2) STR + RT(0/2)
STR(1) STR(0/1)
PR(3) PR(3/3)
PR + RT(4) PR + RT(3/4)
Rades et al. [9] 2006 438 GTR(152) 99 99 84 74 44 mo N/A
GTR + RT(43) 97 97 87 87 (12–456)
IR(109) 82 82 41 35
IR + RT(134) 89 89 83 76
Abbreviations: GTR gross total resection, STR subtotal resection, PR partial resection, Bx biopsy, OS overall survival, LC local control, LR local recurrence, N/A not
applicable, F/U follow-up, IR incomplete resection, RT radiotherapy.
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was caused by surgery in two patients and by cerebral in-
farction 5 years after RT in the third patient. Although
vasculopathy with stroke are rare sequelae of irradiation
[22], it is still possible that they are related to adjuvant RT.
Nonetheless, this is only a speculation, and this possible
association should be studied further in future studies.
The most common late neurotoxicity was short-term
memory impairment, which had no impact on the daily
life and work of the affected patients. It is not clear
whether this is related to RT, because the records of
acute toxicity after surgery are incomplete. It has been
reported that radiation doses to key structures such as
the hippocampus may lead to long-term memory effects
[23,24]; however, dosimetric comparison of the group
with memory impairment and the group without mem-
ory impairment showed that the mean and maximumdoses applied to the hippocampus did not differ signifi-
cantly. Therefore, it seems that it is unlikely that RT was
the main cause of the memory deficit. Instead, some
studies [25,26] have shown that surgical resection has
adverse effects on memory in patients in whom the
tumor is located in the lateral ventricle and/or the third
ventricle. Friedman et al. [26] retrospectively analyzed
the neuropsychological data of 33 patients who received
surgical treatment for brain tumors in the third ven-
tricle: 43% of the patients displayed particularly severe
memory impairment. Moreover, Shi et al. [27] showed
that CN patients who underwent surgical resection
showed impaired memory function in comparison with
healthy individuals. In contrast, with regard to the effect
of RT, most prospective studies [28-33] investigating
radiation-induced neurotoxicity in low-grade glioma
patients did not find a relationship between RT and
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gested a decline in cognitive function after RT were
retrospective and often included a small number of pa-
tients [34]. Therefore, based on the published findings,
we believe that the late neurotoxicities observed in our
study were predominantly caused by surgery. Taken to-
gether, the findings in our study imply that the adverse ef-
fects of adjuvant RT for CN patients are limited and
acceptable. Thus, in patients for whom it is difficult to
perform GTR, IR with adjuvant RT avoids the potential
risk of complications associated with a radical surgical
approach.
Based on some studies, another reason for defering RT
in patients who undergo IR is that they may be success-
fully salvaged with surgery or radiation in case of disease
progression, these authors suggested that careful surveil-
lance alone after IR may be a safe strategy [5,13]. How-
ever, other authors [9] argued that both OS and LC were
important endpoints. At the time of recurrence, initially
benign neurocytomas may be associated with severe
complications such as craniospinal dissemination and in-
traventricular hemorrhage [35,36]. A second cranial op-
eration appears to entail significant risk. Therefore, in
our opinion, RT would be more effective if the tumor
burden is minimal, and lower radiation dose and a lim-
ited radiation field are feasible at the time. The benefits
of adjuvant RT seemed to overweigh its potential risks
for CN patients after IR. Although it is hard to draw a
conclusion based on the small sample size in this retro-
spective study, we believe that the role of adjuvant RT
should be re-evaluated for these patients. Longer follow-
up is needed to further investigate this issue.
For CN patients who undergo GTR, most authors
agree that the clinical outcomes are favorable. Rades
et al. [9] reviewed 152 CN cases of GTR and found the
5-year OS and 5-year LC to be 99% and 84%, respect-
ively; these results are in accordance with ours (94.4%
and 95%, respectively). All these data suggest that GTR
alone is sufficient for the treatment of most CN patients.
In our study, two patients who underwent biopsy and
RT (one underwent surgery 6 months after RT) survived
for 65 and 91 months without tumor progression. Simi-
lar to these cases, Leenstra et al. [3] summarized a total
of 11 cases in which the patients were treated with con-
ventional RT alone after stereotactic biopsy; tumor relapse
occurred in only three cases. These limited data suggest
that RT may be the treatment of choice for CN patients
who undergo biopsy and do not require resection.
The optimal target volume of adjuvant RT for CN re-
mains unclear because the data for this are scarce. Fol-
lowing the generally accepted guidelines for low-grade
brain tumors, many institutions adopt a target volume
that includes the preoperative tumor volume and a 2-cm
margin [37]. Since CNs are indolent tumors and aremostly confined to the lateral ventricles without invasion
to the surrounding brain parenchyma, we think that the
target volume maybe somewhat different from that of
other low-grade brain tumors. In recent years, we have
performed conformal irradiation with a 10-mm clinical
target volume margin in order to reduce the adverse ef-
fects of RT. Although the follow-up time was relatively
short, no recurrence was observed in our patients. In the
most recent largest prospective study [33] addressing the
late effects in 78 pediatric patients with low-grade gli-
oma treated with 3D-CRT, a 10-mm clinical target vol-
ume margin was routinely used; the results showed that
the adverse effects were limited and predictable for most
patients. Moreover, the 10-year OS and 10-year event-
free survival were 96% and 75%, respectively. According
to these limited data, we think that a 10-mm clinical tar-
get volume margin may be sufficient for CN patients
who undergo 3D-CRT.
The optimal radiation dose for CN patients also re-
mains unclear. The study by Rades [37] is the only one
that investigates the appropriate radiation dose after IR;
according to this study, a dose of ≥54 Gy significantly
improves local control in patients with subtotally resected
neurocytomas. However, in contrast to these findings, in
our study, most of the patients received a total dose of
50–54 Gy, and higher doses (≥54 Gy) were not found to
have an impact on clinical outcomes. Thus, a total dose of
50–54 Gy may be appropriate for CN patients who
undergo IR.
One of the limitations in our study is that the MIB-1
labeling index of CN was not routinely examined at
Tiantan Hospital in the past. The MIB-1 labeling index
for this tumor is usually low, less than 2%, and tumors
with indices greater than 2% or 3% have been referred to
as “atypical neurocytomas” and are associated with a sig-
nificantly shorter recurrence-free interval [18-20]. How-
ever, a recent large multicenter study of 71 cases by
Vasiljevic and co-workers [7] reported that histologic
criteria may not be reliable markers for “atypical” CNs,
and that the extent of surgery was the main prognostic
factor. Further, the long-term clinical results of 58 CN
patients also challenged previous reports that the MIB-1
labeling index is related to the risk of recurrence [38]. In
light of these reports, it seems that more reliable criteria
are needed to define atypical groups of CNs.
Conclusions
In CN patients who undergo IR, the addition of adjuvant
RT leads to survival outcomes comparable to those of
patients who undergo GTR. The excellent outcomes and
low incidence of late toxicities suggest that adjuvant RT
may play an important role in the treatment of CN
patients after IR, considering that treatment with IR
alone may lead to disease progression. A multicenter
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vestigate the optimal parameters for adjuvant RT in CN
patients.
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